The product can not be sold in a country where it is illegal.

Buy 3-MeO-PCMo for sale online - USA vendor

Product Name: 3-MeO-PCMo
IUPAC Name: 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine
Other Names: 3-MeO-PCMo
Molecular Formula: None
Molar Mass: 237.26 g·mol−1
Effect: stimulant, psychedelic
Purity of the substance: 99.9%
Physical properties: Crystals, Powder
Buy 3-MeO-PCMo for sale online - USA vendor
In Stock

- FREE shipping, 6-7 days delivery time
- Inner sending exist.
The main payment option is Bitcoin. As extra ways WU, MG.
We alwayse provide FREE samples of Top products with the main order.

Loyalty program exist, second order will be - 5%OFF

Safely work only with us! We provide - re-shipment guarantees.

Here you'll discover unused lawful items of immaculate quality.

Some time recently purchase if you don't mind make beyond any doubt that the items beneath your curiously are lawful in your country.

We do not offer a pharmaceutical items or beneath control items.

Table of Contents

  1. Investigating 3-MeO-PCMo: Chemistry and Pharmacology
  2. Investigating 3-MeO-PCMo: Dosage Guidelines
  3. Investigating 3-MeO-PCMo: Physical, Visual, and Cognitive Effects
  4. Investigating 3-MeO-PCMo: Legal Status
  5. Frequently Asked Questions (FAQ)


3-MeO-PCMo (4-[1-(3-methoxyphenyl)cyclohexyl]morpholine) emerges as a novel morpholine analogue of 3-MeO-PCP, presenting intriguing pharmacological properties. Belonging to the arylcyclohexylamine chemical class, it exhibits dissociative NMDA receptor antagonist effects, acts as a sigma receptor agonist, and possesses anesthetic properties. Despite its potency being less than 1/10th of 3-MeO-PCP, it induces a state known as "dissociative anesthesia," making it attractive for recreational use.

Pharmacological Profile

Dissociative Anesthesia

Upon ingestion, 3-MeO-PCMo induces a state characterized by dissociative anesthesia. This state involves a profound separation of sensory input from conscious awareness, often leading to altered perceptions, hallucinations, and detachment from the surrounding environment.

Mechanism of Action

As an NMDA receptor antagonist, 3-MeO-PCMo interferes with the normal functioning of N-methyl-D-aspartate receptors, disrupting glutamate transmission. Additionally, its sigma receptor agonist properties contribute to its anesthetic effects, although the exact mechanism remains to be fully elucidated.

Availability and Usage

Online Availability

In recent times, 3-MeO-PCMo has become readily accessible through online research chemical vendors. Its availability on these platforms has facilitated its dissemination as a designer drug, attracting individuals seeking novel psychoactive experiences.

Recreational Use

Primarily marketed as a recreational substance, 3-MeO-PCMo is sought after by individuals interested in exploring its dissociative effects. However, the lack of comprehensive understanding regarding its pharmacology and long-term effects raises concerns regarding its safety and potential for misuse.

Research Landscape

While 3-MeO-PCMo itself remains relatively understudied, previous research on morpholine analogues of phencyclidine provides a foundation for understanding its potential effects and mechanisms of action. Further investigation into its pharmacological profile is warranted to better comprehend its risks and benefits.

In conclusion, 3-MeO-PCMo represents a novel addition to the landscape of dissociative drugs, offering unique pharmacological properties and recreational potential. However, its widespread availability and limited understanding necessitate careful consideration of its implications for public health and safety. Further research is imperative to unravel the full spectrum of its effects and inform regulatory measures aimed at mitigating potential harms associated with its use.

Investigating 3-MeO-PCMo: Chemistry and Pharmacology


3-MeO-PCMo, or 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine, belongs to the arylcyclohexylamine class of drugs. These compounds are characterized by a cyclohexane ring bound to an aromatic ring, along with an amine group at the same location. In the case of 3-MeO-PCMo, the aryl substituent is a phenyl ring with a methoxy (CH3-O-) substituent at R3, linked to a six-membered cyclohexyl ring. The amine group at R1 on the cyclohexyl ring is incorporated into a morpholine ring as R4.

Morpholine, a six-membered heterocyclic ring with an oxygen substituent at R1, distinguishes 3-MeO-PCMo as a morpholine analogue of 3-MeO-PCP, which lacks an oxygen moiety in its six-membered amine ring (a piperidine ring instead of a morpholine ring).


The pharmacological profile of 3-MeO-PCMo remains poorly understood due to limited research. However, based on its structural similarities and subjective effects comparable to other arylcyclohexylamine dissociatives such as 3-MeO-PCP, PCP, and MXE, it is hypothesized to act as an NMDA receptor antagonist.

NMDA receptors facilitate electrical signal transmission between neurons in the brain and spinal column. To pass signals, the receptor must be open, but dissociatives like 3-MeO-PCMo close NMDA receptors by blocking them. This blockade leads to a disconnection of neurons, resulting in loss of sensation, impaired movement, and potentially the characteristic "K-hole" experience associated with this class of substances.

Subjective Effects

Disclaimer: The effects outlined below are sourced from the Subjective Effect Index (SEI), based on anecdotal user reports and analyses by PsychonautWiki contributors. While informative, these effects should be viewed with skepticism.

It's important to note that these effects may not manifest predictably or reliably, with higher doses increasing the likelihood of experiencing the full spectrum of effects. Moreover, higher doses also raise the risk of adverse effects, including addiction, severe injury, or even death.

Investigating 3-MeO-PCMo: Dosage Guidelines

Dosage Ranges

Understanding appropriate dosage ranges is crucial for safe and responsible use of 3-MeO-PCMo. The following dosage guidelines provide a framework for users to gauge their intake and minimize the risk of adverse effects.

  • Threshold: 50 mg
  • Light: 100 - 200 mg
  • Common: 200 - 300 mg
  • Strong: 300 - 400 mg
  • Heavy: 400 mg and above

Threshold Dose

The threshold dose for 3-MeO-PCMo is reported to be approximately 50 mg. At this level, users may begin to perceive subtle effects, although they may not be fully pronounced.

Light Dose

A light dose of 3-MeO-PCMo typically ranges from 100 to 200 mg. At this dosage, users may experience mild to moderate effects, including altered perceptions, changes in sensory experience, and mild dissociation.

Common Dose

The common dose falls within the range of 200 to 300 mg. At this level, users can expect more pronounced effects, with a deeper state of dissociation, enhanced sensory distortions, and increased impairment of motor function.

Strong Dose

A strong dose of 3-MeO-PCMo ranges from 300 to 400 mg. At this dosage, users may experience intense dissociation, profound alterations in perception, and significant impairment of motor skills. It is crucial for individuals to exercise caution and mindfulness at this level due to the potential for overwhelming effects.

Heavy Dose

Doses exceeding 400 mg are considered heavy and pose a significant risk of adverse effects. At this level, users may experience extreme dissociation, loss of bodily awareness, and heightened susceptibility to dangerous behavior. Heavy doses greatly increase the likelihood of negative outcomes and should be avoided to mitigate potential harm.

Investigating 3-MeO-PCMo: Physical, Visual, and Cognitive Effects

Physical Effects

  • Nausea: High doses of 3-MeO-PCMo may induce nausea and vomiting, though users often find the experience less unpleasant due to the detachment from physical senses.
  • Motor Control Loss: Gross and fine motor control, balance, and coordination may be significantly impaired, especially at higher doses. Users should ensure a safe environment to prevent injury.
  • Perception of Bodily Lightness: Users may feel a sensation of weightlessness, encouraging physical activity due to the perceived lightness and ease of movement.
  • Physical Autonomy: A sense of autonomy over bodily movements may be experienced.
  • Physical Euphoria: Pleasurable physical sensations, often described as warm and tingling, may envelop the body.
  • Spatial Disorientation: Users may experience difficulties in spatial awareness and orientation.
  • Spontaneous Physical Sensations: A pleasurable tingling sensation may be felt across the body, enhancing the overall sensory experience.
  • Tactile Disconnection and Suppression: Sensory input and tactile sensations may be diminished or disconnected.

Visual Effects

  • Suppression: Visual suppression may occur, leading to reduced clarity and intensity of visual perception.
  • Double Vision: Moderate to heavy doses can result in double vision, making reading difficult without closing one eye.
  • Frame Rate Suppression: Users may perceive a reduction in the rate at which visual information is processed.
  • Pattern Recognition Suppression: Higher doses may hinder the ability to recognize and interpret visual patterns and data.
  • Visual Acuity Suppression: Visual acuity may be diminished.
  • Visual Disconnection: Users may experience dissociative visual effects, including the perception of holes, spaces, and voids.

Cognitive Effects

The cognitive effects of 3-MeO-PCMo encompass various subcomponents:

  • Amnesia
  • Anxiety Suppression
  • Consciousness Disconnection
  • Compulsive Redosing
  • Conceptual Thinking
  • Creativity Enhancement
  • Déjà Vu
  • Depersonalization
  • Derealization
  • Disinhibition
  • Dream Potentiation
  • Existential Self-Realization
  • Euphoria
  • Memory Suppression
  • Ego Death
  • Immersion Enhancement
  • Increased Music Appreciation
  • Analysis Suppression
  • Introspection
  • Mania
  • Time Distortion
  • Thought Deceleration

Auditory Effects

  • Suppression: Auditory suppression may occur, reducing the clarity and intensity of auditory perception.
  • Distortions: Auditory distortions, including alterations in pitch or tone, may be experienced.
  • Hallucinations: Auditory hallucinations, such as hearing sounds that are not present, may occur.

Urinary Tract Effects

Long-term use of 3-MeO-PCMo may lead to urinary tract problems similar to those associated with ketamine and MXE, but potentially more severe due to the higher doses required. Symptoms may include urinary frequency, urgency, pressure, pelvic and bladder pain, hematuria, and incontinence. These issues can be avoided by limiting usage.

Legal Status

3-MeO-PCMo's legal status varies worldwide. It is commonly available through online research chemical vendors, but possession may still carry legal risks:

  • Germany: Controlled under the NpSG (New Psychoactive Substances Act) since July 18, 2019.
  • Switzerland: Listed under Verzeichnis E as a controlled substance.
  • United Kingdom: Illegal to produce, supply, or import under the Psychoactive Substance Act since May 26th, 2016. Simple possession is not criminalized.

Frequently Asked Questions (FAQ)

1. What is 3-MeO-PCMo?

3-MeO-PCMo, or 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine, is a novel morpholine analogue of 3-MeO-PCP. It belongs to the arylcyclohexylamine class of drugs and exhibits dissociative NMDA receptor antagonist effects, sigma receptor agonist properties, and anesthetic effects.

2. What are the typical dosages of 3-MeO-PCMo?

  • Threshold: 50 mg
  • Light: 100 - 200 mg
  • Common: 200 - 300 mg
  • Strong: 300 - 400 mg
  • Heavy: 400 mg and above

3. What are the physical effects of 3-MeO-PCMo?

Physical effects may include nausea, motor control loss, perception of bodily lightness, physical autonomy, euphoria, spatial disorientation, spontaneous physical sensations, tactile disconnection, and suppression.

4. What are the visual effects of 3-MeO-PCMo?

Visual effects may include suppression, double vision, frame rate suppression, pattern recognition suppression, visual acuity suppression, visual disconnection, distortions, and perspective distortions.

5. What are the cognitive effects of 3-MeO-PCMo?

Cognitive effects may include amnesia, anxiety suppression, consciousness disconnection, compulsive redosing, conceptual thinking, creativity enhancement, déjà vu, depersonalization, derealization, disinhibition, dream potentiation, existential self-realization, euphoria, memory suppression, ego death, immersion enhancement, increased music appreciation, analysis suppression, introspection, mania, time distortion, and thought deceleration.

6. What is the legal status of 3-MeO-PCMo?

The legal status of 3-MeO-PCMo varies by country. It is often available through online research chemical vendors, but possession may carry legal risks in some jurisdictions. Consult local laws for specific information.

7. Are there any potential dangers associated with 3-MeO-PCMo use?

Long-term use of 3-MeO-PCMo may lead to urinary tract problems similar to those associated with other arylcyclohexylamines. Additionally, combining 3-MeO-PCMo with other substances, particularly stimulants or depressants, can pose serious health risks. Always research potential interactions and practice harm reduction techniques.

1kg $1590

100mg $840

1kg $1590

100g $600

1kg $1590

1kg $1590

200g $690

1kg $1690

500g $1080

1kg $1890

100mg $840

1kg $1590